Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer

Por Rabatic, Bryan M., Kong, Feng-Ming (Spring)
Publicado no Transl Lung Cancer Res (2016)

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor...

Por Brizzi, Maria Felice, Defilippi, Paola
Publicado no Transl Lung Cancer Res (2013)

Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer

Por Viteri, Santiago, González-Cao, María, Barrón, Feliciano, Riso, Aldo, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance

Por Remon, Jordi, Majem, Margarita
Publicado no Transl Lung Cancer Res (2013)

Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis

Por Chakravarti, Nitin, Prieto, Victor G.
Publicado no Transl Lung Cancer Res (2015)

Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way...

Por Pilotto, Sara, Molina-Vila, Miguel Angel, Karachaliou, Niki, Carbognin, Luisa, Viteri, Santiago, González-Cao, Maria, Bria, Emilio, Tortora, Giampaolo, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer

Por Pilotto, Sara, Carbognin, Luisa, Karachaliou, Niki, Garassino, Marina, Cuppone, Federica, Petraglia, Sandra, Rosell, Rafael, Tortora, Giampaolo, Bria, Emilio
Publicado no Transl Lung Cancer Res (2015)

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role

Por Santarpia, Mariacarmela, González-Cao, María, Viteri, Santiago, Karachaliou, Niki, Altavilla, Giuseppe, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Translational Lung Cancer Research, the 7(th) AME Journal indexed in SCIE

Publicado no Transl Lung Cancer Res (2018)

Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?

Por Mountzios, Giannis
Publicado no Transl Lung Cancer Res (2018)

Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells

Por Lan, Dong, Wang, Li, He, Rongquan, Ma, Jie, Bin, Yehong, Chi, Xiaojv, Chen, Gang, Cai, Zhengwen
Publicado no Am J Transl Res (2018)

Influence of chemotherapy on EGFR mutation status

Por Luo, Yung-Hung, Chen, Yuh-Min
Publicado no Transl Lung Cancer Res (2013)

Can population data guide surveillance strategies for second primary lung cancers?

Por Arifin, Andrew J., Corkum, Mark T., Louie, Alexander V.
Publicado no Transl Lung Cancer Res (2018)

Can we use interleukin-1β blockade for lung cancer treatment?

Por Gottschlich, Adrian, Endres, Stefan, Kobold, Sebastian
Publicado no Transl Lung Cancer Res (2018)

Stage III non-small cell lung cancer: escalation matters, but how?

Por Hegde, Aparna Madhukeshwar, Walker, Paul Raymond
Publicado no Transl Lung Cancer Res (2018)

Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach

Por Pine, Sharon R., Ryan, Bríd M.
Publicado no Transl Lung Cancer Res (2018)

Vandetanib in advanced non small cell lung cancer: a promise unfulfilled

Por de Boer, Richard H.
Publicado no Transl Lung Cancer Res (2013)

Quality of life for non-small cell lung cancer patients in the age of immunotherapy

Por Ramirez, Robert A., Lu, Jonathan, Thomas, Katharine E. H.
Publicado no Transl Lung Cancer Res (2018)

Studying the immune landscape in lung cancer models: choosing the right experimental tools

Por Weeden, Clare E., Ah-Cann, Casey, Asselin-Labat, Marie-Liesse
Publicado no Transl Lung Cancer Res (2018)

Gefitinib in non-small-cell lung cancer—an old lesson new re-visited

Por Dempke, Wolfram C. M.
Publicado no Transl Lung Cancer Res (2013)